The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Continue advancing our pipeline candidates, with several key updates in 2025, including CTX112™ in oncology and autoimmune ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...